Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...

In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including ...

Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

Medicare GLP-1 Bridge provides Wegovy to eligible beneficiaries for $50/month through 2027, creating a defined access channel for obesity treatment previously largely excluded from Medicare coverage.

Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

QuantumCell received worldwide rights to NeuroRestore/ACD856, with closing contingent on foreign direct investment approvals in Sweden and Denmark under customary regulatory conditions. Financial ...

FDA’s PreCheck Pilot Program aims to de-risk and accelerate domestic capacity buildouts via earlier regulatory interaction, aligning manufacturing policy with supply-chain resilience priorities.

A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...